Genetic Testing for All Women? Not a Solution to the Breast Cancer Epidemic
By Karuna Jaggar,
Huffington Post
| 09. 24. 2014
The perseverance and scientific innovation of Dr. Mary Claire King, the geneticist whose efforts to identify the BRCA genes were initially scoffed at by her peers, cannot be underestimated or underappreciated. Her drive and desire to find better tools to address the breast cancer epidemic are shared by activists, researchers, geneticist, and patients alike. But her new recommendation, published in the Journal of the American Medical Association -- that all women in the United States over age 30 be screened for BRCA mutations linked to breast and ovarian cancer -- fails as a matter of public health to recognize the significant limitations, and harms, of mass genetic testing in the current health care environment.
In proposing that genetic testing for the BRCA1 and BRCA2 genes become routine for all women over age 30, Dr. King focuses only on what she sees as the potential benefit, of identifying women with genetic mutations that increase their risk of cancer, and minimizes the harms that result from exposing all 105,000,000 women age 30 and over in the U.S. to genetic testing without access...
Related Articles
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
By Pam Belluck, The New York Times | 10.17.2025
Before dawn on a March morning, Doug Whitney walked into a medical center 2,000 miles from home, about to transform from a mild-mannered, bespectacled retiree into a superhuman research subject.
First, a doctor inserted a needle into his back to...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...